Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc. (CYDY) is a clinical-stage biotechnology and oncology company whose news flow centers on the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Company announcements frequently highlight progress in solid tumor oncology, particularly metastatic triple-negative breast cancer (mTNBC) and metastatic colorectal cancer (mCRC), as well as broader CCR5-related research.
Investors following CYDY news can expect updates on clinical trial milestones, including Phase 2 studies in mCRC and planned Phase 2 proof-of-concept and combination trials in mTNBC. Press releases and shareholder letters describe retrospective survival analyses, PD-L1 upregulation findings, and the company’s “prime and pair” strategy that combines leronlimab with immune checkpoint inhibitors. Conference-related news often covers poster and oral presentations at major oncology meetings such as the San Antonio Breast Cancer Symposium, European Society for Medical Oncology events, and AACR specialty conferences.
CytoDyn’s news stream also includes corporate and regulatory developments. Recent items have addressed the resolution of government investigations, an agreement in principle to settle a securities class action lawsuit, and stockholder approval of amendments to increase authorized common shares. Financing updates, such as the Standby Equity Purchase Agreement with Yorkville, provide insight into how the company plans to support its clinical programs.
In addition, CytoDyn issues periodic letters to shareholders that summarize operational rebuilding, regulatory interactions, and collaborations with academic centers in areas like glioblastoma, Alzheimer’s disease, and HIV cure research. For readers tracking CYDY, this news page offers a consolidated view of scientific data releases, trial progress, financing arrangements, and governance actions that shape the company’s development trajectory.
CytoDyn Inc. announced a leadership transition plan following the termination of Nader Z. Pourhassan as President and CEO, effective January 24, 2022. Antonio Migliarese, previously CFO, has been appointed interim President while retaining his role as CFO. The Board has initiated a search for a new permanent CEO with pharmaceutical experience to advance the regulatory approval and commercialization of leronlimab. Scott A. Kelly will step down as Chairman but remain on the Board, with Tanya Durkee Urbach taking over as Chairman. The executive team remains committed to the Company's objectives.
CytoDyn Inc. (OTCQB: CYDY) has announced the cancellation of its webcast scheduled for January 13, 2022, with plans to provide updates at a future date. The company is focused on developing leronlimab, a CCR5 antagonist aimed at treating HIV and metastatic cancer. FDA has granted Fast Track designation for leronlimab in two indications: HIV combination therapy and metastatic triple-negative breast cancer (mTNBC). CytoDyn has conducted 16 clinical trials with over 1,200 participants and aims to resubmit its Biologics License Application for leronlimab in the near future.
CytoDyn Inc. (OTCQB: CYDY) announces an investment community webcast on January 13, 2022, to discuss updates on NASH data, cancer, COVID-19, HIV BLA, and the company's financials. Key figures participating include CEO Nader Pourhassan and CMO Scott Kelly, among others. The discussion will last 60 minutes, including a live Q&A session. CytoDyn is developing leronlimab, a CCR5 antagonist with multiple therapeutic applications, and aims to resubmit its BLA for HIV therapy by Q1 2022 after previous setbacks.
CytoDyn (OTCQB: CYDY) announced significant developments regarding its lead drug, leronlimab, in treating HIV. The company achieved a primary endpoint in a pivotal Phase 3 trial involving heavily treatment-experienced (HTE) patients, with over 20 individuals remaining in an extension study for up to four years. Findings from a study demonstrating leronlimab's activity against 4-class drug-resistant HIV-1 will be included in its Biologics License Application (BLA) submission. Notably, leronlimab showcases potential benefits over other treatments, such as lower toxicity and less frequent dosing.
CytoDyn Inc. announced positive results from its Phase 2 clinical trial for leronlimab, a potential treatment for nonalcoholic steatohepatitis (NASH). The trial achieved its primary endpoint (PDFF) for the 350 mg weekly dose, with statistically significant results compared to placebo. The secondary endpoint (cT1) also showed near significance. This short 14-week trial demonstrates the potential of leronlimab, especially as there are no approved pharmacological therapies for NASH. Further analysis of biomarker data is ongoing to understand responder rates.
CytoDyn has secured a court ruling allowing access to clinical trial data from its former Contract Research Organization, Amarex. The U.S. District Court for the District of Maryland granted a preliminary injunction requiring Amarex to provide CytoDyn with full access to its electronic data capture systems. The ruling follows allegations that Amarex breached contractual obligations, causing significant damages. CytoDyn must post a $6.5 million bond by January 14, 2022. The company is developing leronlimab, targeting multiple indications, including HIV and metastatic cancer.
CytoDyn has received FDA approval to initiate a Phase 3 clinical trial assessing leronlimab for critically ill COVID-19 patients requiring invasive mechanical ventilation or ECMO. The trial will randomly assign patients to receive up to four IV doses of 700 mg leronlimab or placebo alongside standard care. The company aims to address the urgent need for effective COVID-19 treatments as cases surge in the U.S. Leronlimab has previously shown positive outcomes in early trials, with over 100 eINDs accepted by the FDA.
CytoDyn (OTCQB: CYDY) announced preliminary results from its Phase 2 trial for treating NASH with leronlimab. Over 14 weeks, patients showed an average cT1 reduction of 31.2 msec. Notably, 5 of 6 patients with severe NASH experienced an average cT1 drop of 108 msec and a 20% reduction in fatty deposits. The trial, involving 20 patients, aims to assess the drug's efficacy against liver fibrosis, with broader implications for the urgent need for NASH treatments, as no FDA-approved options currently exist.
CytoDyn Inc. (OTCQB: CYDY) will host an investment community webcast on December 14, 2021, featuring key executives discussing the company's developments, particularly on leronlimab, a CCR5 antagonist. The 60-minute session includes a 20-minute presentation followed by a 40-minute Q&A segment. CytoDyn is focused on advancing its BLA for HIV therapy and exploring further indications for leronlimab, including potential treatments for COVID-19 long-haulers and various solid tumors. More details can be found on their official site.
CytoDyn has engaged the FDA regarding the development of leronlimab for critically ill COVID-19 patients, finding the project's feasibility promising amid a decline in hospitalizations. The company has submitted a Phase 3 clinical trial to evaluate leronlimab's efficacy combined with standard care for patients needing invasive mechanical ventilation or ECMO. Prior Phase 3 results indicated an 82% survival rate in a subgroup after two doses. The new trial aims for improved outcomes with four doses. CytoDyn remains optimistic about its pipeline across various therapeutic areas.